These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23590635)

  • 1. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis.
    Knight S; Collins M; Takeuchi Y
    Curr Gene Ther; 2013 Jun; 13(3):211-27. PubMed ID: 23590635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
    Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
    Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: Oncogenic Insertional Mutagenesis as a Consequence of Retroviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Disease.
    Ahmed B; Zafar M; Qadir MI
    Crit Rev Eukaryot Gene Expr; 2019; 29(6):511-520. PubMed ID: 32422006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retroviral Insertional Mutagenesis in Humans: Evidence for Four Genetic Mechanisms Promoting Expansion of Cell Clones.
    Bushman FD
    Mol Ther; 2020 Feb; 28(2):352-356. PubMed ID: 31951833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.
    Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C
    Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
    Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
    Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
    Trobridge GD
    Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrovirus-induced oncogenesis and safety of retroviral vectors.
    Nair V
    Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing the genotoxic potential of retroviral vectors.
    Ramezani A; Hawley TS; Hawley RG
    Methods Mol Biol; 2008; 434():183-203. PubMed ID: 18470646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
    Doi K; Takeuchi Y
    Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells.
    Bosticardo M; Ghosh A; Du Y; Jenkins NA; Copeland NG; Candotti F
    Mol Ther; 2009 Nov; 17(11):1910-8. PubMed ID: 19638958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for severe combined immunodeficiencies and beyond.
    Fischer A; Hacein-Bey-Abina S
    J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors.
    Haviernik P; Bunting KD
    Curr Gene Ther; 2004 Sep; 4(3):263-76. PubMed ID: 15384940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insertional oncogenesis by non-acute retroviruses: implications for gene therapy.
    Fan H; Johnson C
    Viruses; 2011 Apr; 3(4):398-422. PubMed ID: 21994739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
    Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
    Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retroviral vectors for gene therapy.
    Maier P; von Kalle C; Laufs S
    Future Microbiol; 2010 Oct; 5(10):1507-23. PubMed ID: 21073311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological promoters reduce the genotoxic risk of integrating gene vectors.
    Zychlinski D; Schambach A; Modlich U; Maetzig T; Meyer J; Grassman E; Mishra A; Baum C
    Mol Ther; 2008 Apr; 16(4):718-25. PubMed ID: 18334985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroviral mutagenesis of cellular oncogenes: a review with insights into the mechanisms of insertional activation.
    Kung HJ; Boerkoel C; Carter TH
    Curr Top Microbiol Immunol; 1991; 171():1-25. PubMed ID: 1814689
    [No Abstract]   [Full Text] [Related]  

  • 19. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
    Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
    PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives.
    Vargas JE; Chicaybam L; Stein RT; Tanuri A; Delgado-Cañedo A; Bonamino MH
    J Transl Med; 2016 Oct; 14(1):288. PubMed ID: 27729044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.